{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:32:50Z","timestamp":1790548370878,"version":"4.1.0"},"reference-count":44,"publisher":"Oxford University Press (OUP)","issue":"suppl_3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,2,1]]},"DOI":"10.1093\/cid\/ciq119","type":"journal-article","created":{"date-parts":[[2011,1,10]],"date-time":"2011-01-10T01:43:13Z","timestamp":1294623793000},"page":"s271-s275","source":"Crossref","is-referenced-by-count":53,"title":["Correcting a Public Health Fiasco: The Need for a New Vaccine against Lyme Disease"],"prefix":"10.1093","volume":"52","author":[{"given":"Stanley A.","family":"Plotkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,2,1]]},"reference":[{"key":"key\n\t\t\t\t20171014005956_bib1","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/B978-1-4160-3611-1.50055-6","article-title":"Lyme disease vaccines","volume-title":"Vaccines","author":"Steere","year":"2008"},{"key":"key\n\t\t\t\t20171014005956_bib2","article-title":"Overview of vaccines","volume-title":"Readings in global health, a research anthology collected from the American Journal of Public Health","author":"Plotkin","year":"2005"},{"key":"key\n\t\t\t\t20171014005956_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0950268806007096","article-title":"The Lyme vaccine: a cautionary tale","volume":"135","author":"Nigrovic","year":"2007","journal-title":"Epidemiol Infect"},{"key":"key\n\t\t\t\t20171014005956_bib4","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0002-9343(95)99915-9","article-title":"The clinical spectrum of early Lyme borreliosis in patients with culture-confirmed erythema migrans","volume":"100","author":"Nadelman","year":"1996","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20171014005956_bib5","first-page":"1","article-title":"Surveillance for lyme disease\u2013United states, 1992-2006","volume":"57","author":"Bacon","year":"2008","journal-title":"MMWR Surveill Summ"},{"key":"key\n\t\t\t\t20171014005956_bib6","first-page":"14","volume-title":"Lyme disease\u2014Connecticut 2008","author":"Anonymous","year":"2009","edition":"29th ed"},{"key":"key\n\t\t\t\t20171014005956_bib7","article-title":"Lyme borreliosis: Europe-wide coordinated surveillance and action needed?","volume":"11","author":"Smith","year":"2006","journal-title":"Euro Surveill"},{"key":"key\n\t\t\t\t20171014005956_bib8","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1056\/NEJM199807233390402","article-title":"A vaccine consisting of recombinant borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium","volume":"339","author":"Sigal","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014005956_bib9","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJM199807233390401","article-title":"Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group","volume":"339","author":"Steere","year":"1998","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014005956_bib10","first-page":"1","article-title":"Recommendations for the use of Lyme disease vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"48","author":"CDC","year":"1999","journal-title":"MMWR Recomm Rep"},{"key":"key\n\t\t\t\t20171014005956_bib11","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3201\/eid1402.070725","article-title":"Effectiveness of personal protective measures to prevent Lyme disease","volume":"14","author":"Vazquez","year":"2008","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t20171014005956_bib12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.amepre.2009.04.026","article-title":"Peridomestic Lyme disease prevention: results of a population-based case-control study","volume":"37","author":"Connally","year":"2009","journal-title":"Am J Prev Med"},{"key":"key\n\t\t\t\t20171014005956_bib13","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/ncprheum0374","article-title":"Strategies for primary and secondary prevention of Lyme disease","volume":"3","author":"Corapi","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"key":"key\n\t\t\t\t20171014005956_bib14","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1001\/jama.279.24.1937-JMN0624-3-1","article-title":"Guarded endorsement for Lyme disease vaccine","volume":"279","author":"Marwick","year":"1998","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20171014005956_bib15","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1128\/IAI.68.2.658-663.2000","article-title":"Occurrence of severe destructive lyme arthritis in hamsters vaccinated with outer surface protein A and challenged with Borrelia burgdorferi","volume":"68","author":"Croke","year":"2000","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20171014005956_bib16","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2217\/fmb.09.17","article-title":"Human Lyme disease vaccines: past and future concerns","volume":"4","author":"Nardelli","year":"2009","journal-title":"Future Microbiol"},{"key":"key\n\t\t\t\t20171014005956_bib17","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.molimm.2007.04.017","article-title":"Human homologues of a Borrelia T cell epitope associated with antibiotic-refractory Lyme arthritis","volume":"45","author":"Drouin","year":"2008","journal-title":"Mol Immunol"},{"key":"key\n\t\t\t\t20171014005956_bib18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1126\/science.281.5377.703","article-title":"Identification of LFA-1 as a candidate autoantigen in treatment-resistant Lyme arthritis","volume":"281","author":"Gross","year":"1998","journal-title":"Science"},{"key":"key\n\t\t\t\t20171014005956_bib19","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1128\/IAI.61.7.2774-2779.1993","article-title":"Association of treatment-resistant chronic Lyme arthritis with HLA-DR4 and antibody reactivity to OspA and OspB of Borrelia burgdorferi","volume":"61","author":"Kalish","year":"1993","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20171014005956_bib20","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1056\/NEJM199007263230402","article-title":"Association of chronic Lyme arthritis with HLA-DR4 and HLA-DR2 alleles","volume":"323","author":"Steere","year":"1990","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171014005956_bib21","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1128\/IAI.69.4.2130-2136.2001","article-title":"DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease","volume":"69","author":"Wallich","year":"2001","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20171014005956_bib22","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/art.24418","article-title":"HLA type and immune response to Borrelia burgdorferi outer surface protein a in people in whom arthritis developed after Lyme disease vaccination","volume":"60","author":"Ball","year":"2009","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20171014005956_bib23","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/S0264-410X(01)00500-X","article-title":"Adverse event reports following vaccination for Lyme disease: December 1998-July 2000","volume":"20","author":"Lathrop","year":"2002","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014005956_bib24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0891-5520(05)70274-9","article-title":"Lyme vaccine: issues and controversies","volume":"15","author":"Rahn","year":"2001","journal-title":"Infect Dis Clin North Am"},{"key":"key\n\t\t\t\t20171014005956_bib25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1017\/S0950268806007394","article-title":"The Lyme vaccine: a cautionary tale","volume":"135","author":"McSweegan","year":"2007","journal-title":"Epidemiol Infect"},{"key":"key\n\t\t\t\t20171014005956_bib26","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1128\/IAI.65.3.882-889.1997","article-title":"Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi","volume":"65","author":"Golde","year":"1997","journal-title":"Infect Immun"},{"key":"key\n\t\t\t\t20171014005956_bib27","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1086\/514779","article-title":"Alternative vaccination schedules (0, 1, and 6 months versus 0, 1, and 12 months) for a recombinant OspA Lyme disease vaccine","volume":"28","author":"Van","year":"1999","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014005956_bib28","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0149-2918(03)90027-0","article-title":"An open-label, nonrandomized, single-center, prospective extension, clinical trial of booster dose schedules to assess the safety profile and immunogenicity of recombinant outer-surface protein A (OspA) Lyme disease vaccine","volume":"25","author":"Schoen","year":"2003","journal-title":"Clin Ther"},{"key":"key\n\t\t\t\t20171014005956_bib29","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1542\/peds.108.1.123","article-title":"Safety and immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against lyme disease in healthy children and adolescents: a randomized controlled trial","volume":"108","author":"Sikand","year":"2001","journal-title":"Pediatrics"},{"key":"key\n\t\t\t\t20171014005956_bib30","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1086\/317479","article-title":"Reactogenicity and immunogenicity of a Lyme disease vaccine in children 2-5 years old","volume":"31","author":"Beran","year":"2000","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014005956_bib31","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0022-3476(99)70055-7","article-title":"Immunogenicity of a recombinant Borrelia burgdorferi outer surface protein A vaccine against Lyme disease in children","volume":"135","author":"Feder","year":"1999","journal-title":"J Pediatrics"},{"key":"key\n\t\t\t\t20171014005956_bib32","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1002\/art.10270","article-title":"Cost-effectiveness analysis of the Lyme disease vaccine","volume":"46","author":"Hsia","year":"2002","journal-title":"Arthritis Rheum"},{"key":"key\n\t\t\t\t20171014005956_bib33","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/archinte.161.4.554","article-title":"The cost-effectiveness of vaccination against Lyme disease","volume":"161","author":"Shadick","year":"2001","journal-title":"Arch Intern Med"},{"key":"key\n\t\t\t\t20171014005956_bib34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3201\/eid0503.990302","article-title":"The cost effectiveness of vaccinating against Lyme disease","volume":"5","author":"Meltzer","year":"1999","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t20171014005956_bib35","doi-asserted-by":"crossref","first-page":"281","DOI":"10.4161\/hv.4661","article-title":"An octavalent lyme disease vaccine induces antibodies that recognize all incorporated OspC type-specific sequences","volume":"3","author":"Earnhart","year":"2007","journal-title":"Hum Vaccin"},{"key":"key\n\t\t\t\t20171014005956_bib36","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.jmb.2005.04.066","article-title":"Structure-based design of a second-generation Lyme disease vaccine based on a C-terminal fragment of Borrelia burgdorferi OspA","volume":"350","author":"Koide","year":"2005","journal-title":"J Mol Biol"},{"key":"key\n\t\t\t\t20171014005956_bib37","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1073\/pnas.0305680101","article-title":"An effective second-generation outer surface protein A-derived Lyme vaccine that eliminates a potentially autoreactive T cell epitope","volume":"101","author":"Willett","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"key\n\t\t\t\t20171014005956_bib38","first-page":"349","article-title":"Vaccines for Lyme disease","volume":"21","author":"Younus","year":"2001","journal-title":"Curr Clin Top Infect Dis"},{"key":"key\n\t\t\t\t20171014005956_bib39","doi-asserted-by":"crossref","first-page":"3687","DOI":"10.1016\/j.vaccine.2005.02.006","article-title":"Multicomponent Lyme vaccine: three is not a crowd","volume":"23","author":"Brown","year":"2005","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014005956_bib40","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.carres.2006.11.014","article-title":"Synthesis of an experimental glycolipoprotein vaccine against Lyme disease","volume":"342","author":"Pozsgay","year":"2007","journal-title":"Carbohydr Res"},{"key":"key\n\t\t\t\t20171014005956_bib41","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/S0264-410X(98)00276-X","article-title":"Safety and immunogenicity of recombinant bacille Calmette-Guerin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine","volume":"17","author":"Edelman","year":"1999","journal-title":"Vaccine"},{"key":"key\n\t\t\t\t20171014005956_bib42","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1586\/14760584.2.5.683","article-title":"Progress and controversy surrounding vaccines against Lyme disease","volume":"2","author":"Hanson","year":"2003","journal-title":"Expert Rev Vaccines"},{"key":"key\n\t\t\t\t20171014005956_bib43","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1128\/CVI.00373-08","article-title":"Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease","volume":"16","author":"LaFleur","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"key\n\t\t\t\t20171014005956_bib44","author":"The Healthy People 2020"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/52\/suppl_3\/s271\/20909442\/ciq119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T03:55:50Z","timestamp":1637121350000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/52\/suppl_3\/s271\/445092\/Correcting-a-Public-Health-Fiasco-The-Need-for-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2,1]]},"references-count":44,"journal-issue":{"issue":"suppl_3","published-online":{"date-parts":[[2011,2,1]]},"published-print":{"date-parts":[[2011,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciq119","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2011,2,1]]},"published":{"date-parts":[[2011,2,1]]}}}